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Abstract 58 
 59 
People living with human immunodeficiency virus (PLWH) have significantly increased risk for 60 
cardiovascular disease in part due to inflammation and immune dysregulation. Clonal 61 
hematopoiesis of indeterminate potential (CHIP), the age-related acquisition and expansion of 62 
hematopoietic stem cells due to leukemogenic driver mutations, increases risk for both 63 
hematologic malignancy and coronary artery disease (CAD). Since increased inflammation is 64 
hypothesized to be both a cause and consequence of CHIP, we hypothesized that PLWH have a 65 
greater prevalence of CHIP. We searched for CHIP in multi-ethnic cases from the Swiss HIV 66 
Cohort Study (SHCS, n=600) and controls from the Atherosclerosis Risk in the Communities 67 
study (ARIC, n=8,111) from blood DNA-derived exome sequences. We observed that HIV is 68 
associated with increased CHIP prevalence, both in the whole study population and in a subset of 69 
230 cases and 1002 matched controls selected by propensity matching to control for 70 
demographic imbalances (SHCS 7%, ARIC 3%, p=0.005). Additionally, unlike in ARIC, ASXL1 71 
was the most commonly implicated mutated CHIP gene. We propose that CHIP may be one 72 
mechanism through which PLWH are at increased risk for CAD. Larger prospective studies 73 
should evaluate the hypothesis that CHIP contributes to the excess cardiovascular risk in PLWH.  74 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20225607doi: medRxiv preprint 
4 
 
Introduction  75 
 76 
As current treatments have rendered human immunodeficiency virus (HIV) a chronic 77 
condition, coronary artery disease has emerged as a major source of morbidity in people living 78 
with human immunodeficiency virus (PLWH). Inflammation and immune dysregulation likely 79 
accelerate CAD risk among PLWH.1 Recently, ‘clonal hematopoiesis of indeterminate potential’ 80 
(CHIP), the age-related acquisition and expansion of leukemogenic mutations (primarily in 81 
DNMT3A, TET2, ASXL1, JAK2) in white blood cells, was found to increase risk for both 82 
hematologic malignancy2,3 and CAD4,5 among asymptomatic individuals in the general 83 
population. The proatherogenic mechanisms for CHIP included heightened inflammation.4,6 84 
Given converging mechanisms promoting CAD risk and increased hematologic malignancy risk 85 
among PLWH, we tested the hypothesis that HIV-infected individuals have heightened 86 
prevalence of CHIP. 87 
 88 
Methods 89 
 90 
We identified CHIP in a multi-ethnic sample of 600 PLWH who had available exome 91 
sequences from the Swiss HIV Cohort Study (SHCS), aged 21-83. The SHCS is a multicenter, 92 
prospective observational study for interdisciplinary HIV research7. Established in 1988, the 93 
SHCS currently comprises more than 20,000 PLWH with median 51 years of age. Samples of 94 
600 patients, used for exome sequencing, were chosen randomly in terms of gender, age, 95 
category of transmission, as well as HIV management and control.8 96 
We utilized a set of 8111 individuals with available exome sequences from the 97 
Atherosclerotic Risk in the Community study (ARIC), aged 45-84 years, as population controls.9 98 
The ARIC study is a prospective longitudinal investigation of the development of atherosclerosis 99 
and its clinical sequelae which enrolled 15,792 individuals aged 45 to 64 years at baseline.10 At 100 
study enrollment (1987-1989), the participants were selected by probability sampling from four 101 
United States communities: Forsyth County, North Carolina; Jackson, Mississippi; the 102 
northwestern suburbs of Minneapolis, Minnesota; and Washington County, Maryland. 103 
CHIP was called in both exome sequenced cohorts using a previously described 104 
pipeline.4,11 Briefly, short read sequence data was aligned to the hg19 reference genome using 105 
the BWA-mem algorithm and processed with the Genome Analysis Toolkit MuTect2 tool to 106 
detect somatic variants.12 Identification of individuals with CHIP, used a pre-specified list of 107 
variants in 74 genes known to be recurrent drivers of myeloid malignancies.  108 
As CHIP prevalence depends strongly on age, we performed a 1:5 case/control 109 
propensity matching on age, sex and self-reported ethnicity using nearest neighbor matching13 110 
and requiring an exact match on age as implemented by the MatchIt package version 3.0.2 in R. 111 
Univariate Fisher’s exact test and multivariate logistic regression tested the association between 112 
HIV status and CHIP prevalence. Multivariate models were adjusted for age, sex, self-reported 113 
ethnicity, and smoking status. Analyses were performed in R version 3.6. A threshold of p<0.05 114 
was considered statistically significant. 115 
Written informed consent was obtained from all human participants by each of the 116 
studies with approval of study protocols by ethics committees at participating institutions. 117 
Secondary analysis of the data  in this manuscript was approved by the Mass General Brigham 118 
Institutional Review Board. All relevant ethics committees approved this study and this work is 119 
compliant with all relevant ethical regulations. 120 
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 121 
 122 
Results 123 
 124 
We began by considering the fraction of CHIP across the entire SHCS PLWH cohort 125 
(N=600) and ARIC cohort (N=8111) (Figure 1). SHCS PLWH and ARIC participants had mean 126 
(SD) age 44 (11) and 57 (6) years (p=1.8 x 10-167), were 25% and 56% female (p=1.9 x 10-46), 127 
and were 95% and 74% of European ancestry (p=5.2 x 10-36) respectively. With adjustment for 128 
age, age2, sex and ethnicity, we observed a significant association between HIV case status and 129 
CHIP (OR: 1.77, 95% CI: 1.33-2.21, p=0.02).  130 
Give the overall demographic imbalances, we pursued a propensity matching strategy and 131 
matched datasets by age, gender and ethnicity. Propensity matching analyses yielded a set of 230 132 
PLWH cases and 1002 ARIC population controls. Neither age nor sex, differed significantly  133 
between the matched cohorts (Table 1) and the standardized mean difference across age, sex and 134 
self-reported ethnicity were all less than 0.1 indicative of adequate matching. In this subset, 135 
CHIP was detected in 7% of exomes from PLWH, but only 3% of the controls (Table 1, 136 
univariate p=0.005; multivariate p=0.004).  Of note, the statistical association strengthened 137 
despite a significantly decreased sample size, likely due to the exclusion of younger SHCS 138 
PLWH, who are less likely to have CHIP. Depth of coverage of the four most common CHIP 139 
genes (DNMT3A, TET2, ASXL1, JAK2), when incorporated into the multivariate logistic 140 
regression model, did not affect the results.  141 
 The limited sample size precluded inference on the association of HIV status with 142 
specific CHIP driver genes, however we observed differences in the genes most likely to carry 143 
CHIP mutations between PLWH and population controls. The most common CHIP gene in the 144 
SHCS was ASXL1 (13 out of 27 CHIP mutations, 48%) followed by  TET2 (8 out of 27 CHIP 145 
mutations, 30%) and DNMT3A  (5 out of 27 CHIP mutations, 19%). Overall this distribution was 146 
inverted from the control cohort where CHIP mutations were more frequent in DNMT3A, 147 
followed by TET2 and ASXL1. In total, 22 PLWH had a single CHIP mutation, while one 148 
individual had 2 mutations and one individual had 3 mutations. 149 
 Within the full PLWH cohort (N=600) we considered additional  phenotypes, which 150 
might be a cause or consequence of CHIP. First, we observed a trend toward an increase in CAD 151 
among CHIP carriers (Fisher’s exact test OR: 2.99, p = 0.068). Second, we observed that 152 
duration of antiretroviral therapy (ART) was twice as long in CHIP carriers versus non-carriers ( 153 
ART mean (st. dev.) ART 2675 [1850]  days vs 1322 [1454] days in carriers vs non-carriers 154 
respectively ; p = 0.0004, Mann-Whitney U test). This association was directionally concordant 155 
after adjusting for patient age in multiple logistic regression (p = 0.066) or and remained 156 
significant after matching of 24 CHIP carriers with 24 non-carriers by age (p = 0.042 paired 157 
Mann-Whitney U test). It is important to note that although ART duration positively correlates 158 
with the total duration of HIV infection (Spearman’s rho = 0.58, p=2.0 x 10-54,N = 600), the total 159 
duration of HIV infection is not associated with CHIP p = 0.452; paired Mann-Whitnmey U test 160 
on matched CHIP carriers and non-carriers, p = 0.22] 161 
 162 
Discussion 163 
We here report that HIV associates with increased prevalence of CHIP, a recently 164 
recognized risk factor for blood cancer and CAD. In the present samples, we identify at least 2-165 
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fold enrichment of CHIP among PLWH versus controls when considering known factors 166 
predisposing to CHIP.  167 
HIV infection is linked to accelerated biologic aging and chronic low-grade 168 
inflammation, providing a fertile substrate for CHIP development. Our study is consistent with 169 
another recent study that showed that HIV leads to a greater risk of myelodysplastic syndrome 170 
(MDS), a downstream consequence of CHIP and precursor to myeloid malignancy.14 171 
Furthermore, similar to the gene distribution in MDS, we find a greater relative prevalence of 172 
ASXL1 mutations among PLWH compared to controls. Of note, while cigarette smoking selects 173 
for ASXL1 clonal hematopoiesis15, our cohort of PLWH still had an increased prevalence of 174 
ASXL1 mutations compared to the control cohort despite being well balanced for smoking status 175 
across cohorts. 176 
HIV infection may promote CHIP development through various mechanisms, including 177 
induced immunodeficiency, chronic immune activation from antigenic simulation, as well as 178 
increased prevalence of tobacco smoking and other co-morbid conditions. HIV may induce 179 
CHIP also through the ART which can either increase the rate of somatic mutagenesis or change 180 
the fitness landscape of hematopoietic stem cells or decrease effective population size of blood 181 
cells. HIV may also modify the selective coefficients of specific CHIP mutations. A recent 182 
model proposed that many of the CHIP mutations increase cell fitness, ensuring their 183 
proliferation with age.16 The relative contribution of these factors to CHIP risk, including in the 184 
context of spontaneous viral control and antiretroviral therapy, will require larger studies. An 185 
important limitation of the present study is its cross-sectional nature, but CHIP is highly unlikely 186 
to be a risk factor for HIV acquisition. The relative contribution of these factors to CHIP risk, 187 
including in the context of spontaneous viral control and antiretroviral therapy, will require 188 
larger studies. An important limitation of the present study is its cross-sectional nature, but CHIP 189 
is highly unlikely to be a risk factor for HIV acquisition.  190 
We propose that CHIP may be one mechanism that elevates risk for CAD in PLWH. 191 
Further studies are required to evaluate the hypothesis that CHIP contributes to the excess 192 
cardiovascular risk associated with long-term HIV infection. CHIP may represent a unique 193 
opportunity for precision identification and targeting of CAD risk with particular relevance for 194 
HIV medicine. 195 
 196 
 197 
Data Availability 198 
CHIP genetic variant callsets and associated participant level phenotype data used in this study 199 
are available to qualified investigators by application to the SHCS and ARIC. 200 
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Table 1: Demographics and CHIP association in matched samples 298 
 HIV+ 
Individuals 
(SHCS) 
Population 
Controls 
(ARIC) 
p-value 
n 230 1002  
Age at blood draw, 
mean (st. dev.) 
54.2 (7.4) 55.0 (6.8) 0.12 
Female, N (%) 44 (19%) 240 (24%) 0.086 
Ever smoker, N (%) 143 (62%) 651 (65%) 0.408 
Diabetes mellitus, N (%) 18 (8%) 80 (8%) 0.936 
Black, N (%) 7 (3%) 80 (8%) 0.017 
CHIP carrier, N (%) 16 (7%) 30 (3%) 0.005 
P-value derived from Fisher's exact test for counts and t-test for continuous variables. 299 
 300 
  301 
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 302 
 303 
Figure 1: CHIP prevalence in Swiss HIV Cohort Study and Atherosclerotic Risk in the 304 
Community Study 305 
Upper panel: fraction of cohort observed to have CHIP over time fit with a general additive 306 
model spline. 95% confidence interval displayed as shaded area. Lower panel: Count of number 307 
of individuals with and without CHIP binned by age of time of blood sampling across entire 308 
sequenced cohort. 309 
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